RenovoRx Q3 2026 revenue rises 301% to $1.07M
RenovoRx expects 2026 revenue of $3.75 million to $4.25 million and cash to fund operations for at least 12 months, assuming current plans advance.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
RenovoRx, Inc. (RNXT) reported third-quarter 2026 revenue of $1.066 million, up 301% from $266,000 a year earlier, as RenovoCath sales expanded. Nine-month revenue was $2.538 million versus $885,000. It ended the quarter with 26 active cancer center customers, up from 21 at the end of the second quarter, and expects 2026 revenue of $3.75 million to $4.25 million, with a year-end target of 36 centers.
Q3 net loss was $3.647 million ($0.08 per share), versus $2.912 million ($0.08) a year earlier. Nine-month operating cash use was $9.115 million; cash and equivalents were $10.404 million at September 30, 2026. Management expects cash to fund operations for at least 12 months from issuance, assuming plans advance as contemplated, but says future financing may be needed and the company has no committed capital source.
The Phase III TIGeR-PaC study reached full enrollment in August; initial top-line data are expected in the second half of 2027. The March private placement generated approximately $10.0 million in gross proceeds before fees, and warrant exercises generated approximately $3.5 million through September 30.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointQ3 revenue reached $1.066 million, up 301% year over year.
Negative
- Moderate pointQ3 net loss widened to $3.647 million from $2.912 million.
- Moderate pointNine-month operating cash use was $9.115 million, versus $7.953 million.
Filing Explained
RenovoRx has 22,192,467 outstanding warrants that could add shares and dilute existing ownership, plus a $1.8 million non-cancellable device-purchase commitment.
As of
At that date, RenovoRx had 48,190,073 common shares issued and outstanding; separately, the report lists 22,192,467 warrants, 6,647,650 options and 84,748 unvested restricted stock units as potentially dilutive securities. The warrants represent shares issuable upon exercise, so exercising them would add shares and reduce existing holders’ percentage ownership, absent offsetting changes.
The company says it filed an October 16, 2026 request for SEC consent to withdraw its November 14, 2025 universal Form S-3; that registration statement never became effective and no securities were sold under it. The company says it may consider filing a new universal Form S-3.
Key Figures
Key Terms
Orphan Drug Designation regulatory
interim analysis medical
warrant liability financial
performance obligation financial
incremental borrowing rate financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did RNXT report in Q3 2026?
What is RenovoRx's 2026 revenue forecast?
When does RNXT expect TIGeR-PaC trial data?
How long does RenovoRx expect its cash to last?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
(Mark One)
For the quarterly period ended
OR
For the transition period from ________ to ________
Commission File Number:
(Exact name of registrant as specified in its charter)
|
||
(State or other jurisdiction of incorporation or organization) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
||
(Address of principal executive offices) |
|
(Zip Code) |
(
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ |
Accelerated filer ☐ |
Smaller reporting company |
|
|
Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of October 30, 2026, the registrant had
TABLE OF CONTENTS
Cautionary Note Regarding Forward-Looking Statements |
|
|
|
PART I. FINANCIAL INFORMATION |
1 |
|
|
Item 1. Financial Statements |
1 |
|
|
Condensed Balance Sheets as of September 30, 2026, and December 31, 2025 |
1 |
|
|
Condensed Statements of Operations for the three and nine months ended September 30, 2026 and 2025 |
2 |
|
|
Condensed Statements of Stockholders’ Equity for the three and nine months ended September 30, 2026 and 2025 |
3 |
|
|
Condensed Statements of Cash Flows for the nine months ended September 30, 2026 and 2025 |
5 |
|
|
Notes to the Unaudited Condensed Interim Financial Statements |
6 |
|
|
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations |
18 |
|
|
Item 3. Quantitative and Qualitative Disclosures About Market Risk |
31 |
|
|
Item 4. Controls and Procedures |
31 |
|
|
PART II. OTHER INFORMATION |
32 |
|
|
Item 1. Legal Proceedings |
32 |
|
|
Item 1A. Risk Factors |
32 |
|
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds |
34 |
|
|
Item 3. Defaults Upon Senior Securities |
34 |
|
|
Item 4. Mine Safety Disclosures |
34 |
|
|
Item 5. Other Information |
34 |
|
|
Item 6. Exhibits |
35 |
|
|
SIGNATURES |
37 |
Cautionary Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (this “Report”), particularly in the sections captioned “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to significant risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control. All statements other than present and historical facts and conditions contained in this Report, including statements regarding our commercialization efforts and future revenues, our ongoing clinical trial and other results of operations and financial position, business strategy, plans and our objectives for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” "goal," "aim," “ongoing,” “plan,” “potential,” “predict,” “project,” "future," “should,” “will,” “would,” “in the future” or the negative or derivations of these terms or other comparable terminology referring to the future, although not all forward-looking statements contain such terminology. Actual events or results may differ from those expressed in these forward-looking statements, and these differences may be significant and adverse. Forward-looking statements include, but are not limited to, statements about:
We have based the forward-looking statements contained in this Report primarily on our current expectations and projections about future events and trends that we believe may affect our business, financial condition, results of operations, prospects, business strategy and financial needs. The outcome of the events described in these forward-looking statements is subject to significant risks, uncertainties, assumptions and other factors described in the section titled “Risk Factors” and elsewhere in this Report and in our other SEC filings. These risks are not exhaustive. Other sections of this Report include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Report. We cannot assure you that the results, events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results, events or circumstances could differ materially from those described in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all
potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
The forward-looking statements made in this Report relate only to events as of the date on which such statements are made. We undertake no obligation to update any forward-looking statements after the date of this Report or to conform such statements to actual results or revised expectations, except as required by law.
This Report contains market data and industry forecasts that were obtained from industry publications. These data and forecasts involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such information. We have not independently verified any third-party information. While we believe the market position, market opportunity and market size information included in this Report is generally reliable, such information is inherently imprecise.
In this Report, unless the context otherwise indicates, the terms “RenovoRx,” the “Company,” “we,” “our,” and “us” refer to RenovoRx, Inc., a Delaware corporation. Also, unless the context otherwise indicates, the term "common stock" means the Company's common stock, par value $0.0001 per share.
Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ended in December and the associated quarters, months and periods of those fiscal years.
Part I – FINANCIAL INFORMATION
Item 1. Financial Statements
RenovoRx, Inc.
Condensed Balance Sheets
(Unaudited)
(in thousands, except share and per share amounts)
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Assets |
|
|
|
|
|
|
||
Current assets: |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
|
|
$ |
|
||
Accounts receivable |
|
|
|
|
|
|
||
Prepaid expenses |
|
|
|
|
|
|
||
Inventory |
|
|
|
|
|
|
||
Other current assets |
|
|
|
|
|
|
||
Total current assets |
|
|
|
|
|
|
||
Operating lease right-of-use asset |
|
|
|
|
|
|
||
Property and equipment, net |
|
|
|
|
|
|
||
Other non-current assets |
|
|
|
|
|
|
||
Total assets |
|
$ |
|
|
$ |
|
||
Liabilities and Stockholders’ Equity |
|
|
|
|
|
|
||
Current liabilities: |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
|
|
$ |
|
||
Accrued expenses and other current liabilities |
|
|
|
|
|
|
||
Total current liabilities |
|
|
|
|
|
|
||
Common stock warrant liability |
|
|
|
|
|
|
||
Operating lease liability, net of current portion |
|
|
|
|
|
|
||
Total liabilities |
|
|
|
|
|
|
||
Commitments and contingencies (Note 7) |
|
|
- |
|
|
|
- |
|
Stockholders’ equity: |
|
|
|
|
|
|
||
Common stock, $ |
|
|
|
|
|
|
||
Additional paid-in capital |
|
|
|
|
|
|
||
Accumulated deficit |
|
|
( |
) |
|
|
( |
) |
Total stockholders’ equity |
|
|
|
|
|
|
||
Total liabilities and stockholders’ equity |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these condensed interim financial statements.
1
RenovoRx, Inc.
Condensed Statements of Operations
(Unaudited)
(in thousands, except share and per share amounts)
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Revenues |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Cost of revenue |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss from operations |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
|
|
( |
) |
Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest income, net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Loss on disposition of asset |
|
|
|
|
|
|
|
|
( |
) |
|
|
|
|||
Change in fair value of common stock warrant liability |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
||
Total other income (expense), net |
|
|
( |
) |
|
|
|
|
|
( |
) |
|
|
|
||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Net loss per share - basic and diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Weighted average shares of common stock - basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
The accompanying notes are an integral part of these condensed interim financial statements.
2
RenovoRx, Inc.
Condensed Statements of Stockholders’ Equity
(Unaudited)
(in thousands, except share amounts)
|
|
|
|
Common Stock |
|
|
Additional |
|
|
Accumulated |
|
|
Total |
|
||||||||
|
|
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
|||||
Balance — December 31, 2025 |
|
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
Issuance of common stock upon equity financing, net of issuance cost |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Stock-based compensation expense |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
Balance — March 31, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Issuance of restricted stock awards |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Equity financing costs |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Stock-based compensation expense |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
Balance — June 30, 2026 |
|
|
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Issuance of restricted stock awards |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Issuance of common stock upon exercise of stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Issuance of common stock upon exercise of common stock warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||
Stock-based compensation expense |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
||
Balance — September 30, 2026 |
|
|
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
The accompanying notes are an integral part of these condensed interim financial statements.
3
RenovoRx, Inc.
Condensed Statements of Stockholders’ Equity
(Unaudited)
(in thousands, except share amounts)
|
|
Common Stock |
|
|
Additional |
|
|
Accumulated |
|
|
Total |
|
||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Equity |
|
|||||
Balance — December 31, 2024 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
Issuance of common stock upon equity financing, net of issuance cost |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
Issuance of common stock upon exercise of pre-funded common warrants |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Issuance of restricted stock awards |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Issuance of common stock upon exercise of stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Stock-based compensation expense |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss |
|
- |
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Balance — March 31, 2025 |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Issuance of restricted stock awards |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
'Issuance of common stock upon exercise of stock options |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Issuance of common stock upon exercise of common warrants |
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
Stock-based compensation expense |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss |
|
- |
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Balance — June 30, 2025 |
|
|
|
|
|
|
|
|
|
|
|
( |
) |
|
|
|
||||
Issuance of restricted stock awards |
|
|
|
|
|
|
|
|
|
|
|
|||||||||
Stock-based compensation expense |
|
- |
|
|
|
|
|
|
|
|
|
|
|
|||||||
Net loss |
|
- |
|
|
|
|
|
|
|
( |
) |
|
|
( |
) |
|||||
Balance — September 30, 2025 |
|
|
|
|
$ |
|
|
$ |
|
|
$ |
( |
) |
|
$ |
|
||||
The accompanying notes are an integral part of these condensed interim financial statements.
4
RenovoRx, Inc.
Condensed Statements of Cash Flows
(Unaudited)
(in thousands)
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Cash flows from operating activities: |
|
|
|
|
|
|
||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Stock-based compensation expense |
|
|
|
|
|
|
||
Non-cash lease expense |
|
|
|
|
|
|
||
Change in fair value of common warrants classified as a liability |
|
|
|
|
|
( |
) |
|
Depreciation expense |
|
|
|
|
|
|
||
Loss on disposition of assets |
|
|
|
|
|
|
||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
( |
) |
|
|
( |
) |
Inventory |
|
|
( |
) |
|
|
( |
) |
Prepaid expenses |
|
|
|
|
|
( |
) |
|
Other current assets |
|
|
|
|
|
|
||
Other non-current assets |
|
|
( |
) |
|
|
|
|
Accounts payable |
|
|
|
|
|
|
||
Accrued expenses |
|
|
( |
) |
|
|
( |
) |
Net cash used in operating activities |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
||
Cash flows from investing activities: |
|
|
|
|
|
|
||
Purchase of property and equipment |
|
|
( |
) |
|
|
( |
) |
Net cash used in investing activities |
|
|
( |
) |
|
|
( |
) |
|
|
|
|
|
|
|
||
Cash flows from financing activities: |
|
|
|
|
|
|
||
Proceeds from issuance of common stock and pre-funded common stock warrants |
|
|
|
|
|
|
||
Issuance cost of common stock upon private placement |
|
|
( |
) |
|
|
( |
) |
Proceeds from exercise of common warrants |
|
|
|
|
|
|
||
Proceeds from exercise of stock options |
|
|
|
|
|
|
||
Net cash provided by financing activities |
|
|
|
|
|
|
||
Net increase in cash and cash equivalents |
|
|
|
|
|
|
||
Cash and cash equivalents: |
|
|
|
|
|
|
||
Beginning of period |
|
|
|
|
|
|
||
End of period |
|
$ |
|
|
$ |
|
||
Supplemental disclosure of cash flow information: |
|
|
|
|
|
|
||
Cash paid for income taxes |
|
$ |
|
|
$ |
|
||
Cash paid for interest |
|
$ |
|
|
$ |
|
||
Supplemental disclosure of non-cash investing activities |
|
|
|
|
|
|
||
Right-of-use assets obtained in exchange for modified operating lease obligations, net |
|
$ |
|
|
$ |
|
||
The accompanying notes are an integral part of these condensed interim financial statements.
5
RenovoRx, Inc.
Notes to the Unaudited Condensed Interim Financial Statements
1. Business and Principal Activities
Description of Business
RenovoRx, Inc. (the “Company”, "RenovoRx", "we", "us", "our" or similar terminology) was incorporated in the state of Delaware in December 2012 and operates from its headquarters in Mountain View, California.
The Company is a life sciences company commercializing RenovoCath®, a novel, U.S. Food and Drug Administration (“FDA”)-cleared device for local drug delivery designed to address significant unmet medical needs, with a focus on difficult-to-treat tumors. The Company is also evaluating intra-arterial gemcitabine (known as "IAG") delivered via RenovoCath using RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform as a novel drug-device product candidate for difficult-to-treat locally advanced pancreatic cancer ("LAPC").
The Company's patented TAMP platform, enabled by RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor locally, while potentially minimizing a therapy’s toxicities versus systemic intravenous chemotherapy. The Company's novel approach to targeted drug-delivery offers the potential for increased tolerance and improved safety and efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
The Company is actively commercializing the TAMP platform and RenovoCath as a stand-alone device. The Company's commercial model is currently focused on active commercial cancer center customer expansion, with additional centers driving increased procedures and revenue growth. The Company defines "active" commercial cancer center customers as centers where doctors are actively treating patients with RenovoCath.
Until 2025, the Company primarily focused on evaluating IAG delivered via RenovoCath, through its ongoing Phase III TIGeR-PaC study for LAPC. IAG is currently under investigation and has not been approved for commercial sale. IAG received Orphan Drug Designation ("ODD") for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. In the second quarter of 2026, the Company was granted an additional ODD for oxaliplatin for the treatment of pancreatic cancer.
The Company continues to advance broader clinical programs by generating new data through its continued support of registry studies and investigator-initiated trials ("IITs") in borderline resectable and metastatic pancreatic cancer, use of other agents beyond gemcitabine (the chemotherapy being used in the TIGeR-PaC study), and use of TAMP in other solid tumors. In the second quarter of 2026, the Company began supporting a new IIT study for cholangiocarcinoma, or bile duct cancer, with institutional review board (“IRB”) submission expected by year end 2026. Registry and IIT studies are capital-efficient studies providing meaningful data that may further broaden the application for the TAMP platform which is enabled by RenovoCath.
Liquidity and Capital Resources
From the Company’s inception through September 30, 2026, it has raised an aggregate of approximately $
The Company has incurred significant losses and negative cash flows from operations since its inception. For the nine months ended September 30, 2026, the Company reported a net loss of $
6
The Company believes it will be able, if and when necessary, to raise additional capital through debt financings, private or public equity financings, exercise of outstanding common stock warrants, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance that such financing will be available if and when needed or will be at terms acceptable to the Company. The inability to raise capital as and when needed would have a negative impact on the Company’s liquidity financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve positive cash flows and profitability, and it may never do so.
On October 16, 2026, the Company filed on Form RW, requesting SEC consent to the withdrawal of the Company's universal Registration Statement on Form S-3 filed on November 14, 2025. Such Registration Statement was never declared effective, and no securities were sold in connection under such Registration Statement. The Company will reconsider filing a new universal Form S-3 to allow the Company to access capital via this method.
The accompanying unaudited condensed interim financial statements have been prepared assuming that the Company will continue as a going concern and has reviewed the relevant conditions and events surrounding its ability to continue as a going concern including among others: historical losses, projected future results, negative cash flows from operations, including cash requirements for the upcoming year, funding capacity, net working capital, total stockholders’ equity and future access to capital. Based upon this review and the Company’s current financial condition, the Company has concluded its current cash and cash equivalents will be sufficient to fund its operations through at least the next 12 months from the issuance of these condensed interim financial statements.
2. Summary of Significant Accounting Policies
Basis of Presentation and Unaudited Condensed Interim Financial Information
The accompanying unaudited condensed interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain footnotes or other financial information normally included in unaudited condensed interim financial statements prepared in accordance with GAAP have been condensed or omitted. The unaudited condensed interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The condensed balance sheet as of December 31, 2025 is derived from the Company’s audited financial statements. The results of operations for the three and nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any other future annual or interim period. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and as amended by Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).
There have been no material changes to the significant accounting policies during the nine months ended September 30, 2026, from those previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026 (as amended, the “2025 Annual Report”).
For the nine months ended September 30, 2026, the Company established a Sales Commissions Plan (the “Plan”). The Company incurs incremental costs to obtain customer contracts, primarily in the form of sales commissions. The Company capitalizes such costs when they are expected to be recovered and amortizes the resulting asset over the period of expected benefit. The Company applies the practical expedient under ASC 340-40 to expense such costs when the amortization period that otherwise would have been recognized is one year or less. For the nine months ended September 30, 2026, costs subject to capitalization with an expected benefit greater than one year were not material, and no material contract cost asset was recognized as of September 30, 2026.
Risks and Uncertainties
The Company and its business are subject to a number of significant risks associated with clinical-stage and early commercial stage life science companies, including the risks associated with (i) its relatively early stage commercialization efforts for RenovoCath, (ii) the development of IAG or other product candidates that must receive
7
regulatory approval before market launch, (iii) possible failure of current or future preclinical studies or clinical trials, (iv) dependence on key third parties such as device manufacturers and providers of clinical trial administration services; (v) the need to obtain and maintain insurance coding for its products and product candidates, (vi) dependence on key officer and employees, (vii) competition from larger and more established companies, (viii) obtaining and maintaining intellectual property protections, (ix) changes in the Company’s technology or industry, (x) volatility in the public capital markets and the Company’s ability to maintain the listing of its common stock on Nasdaq, (xi) the Company’s ability to obtain adequate financing when needed to support the Company’s business plan, (xii) the ability to attract and retain additional qualified personnel to manage the anticipated growth of the Company and (xiii) general economic and political conditions.
Use of Estimates
The preparation of the condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, income and expenses as well as the disclosure of contingent assets and liabilities, at the date of the condensed interim financial statements during the reporting periods. In preparing these condensed interim financial statements, management has made its best estimates and judgments of certain amounts included in the condensed interim financial statements. Significant estimates and assumptions made in the accompanying condensed interim financial statements include, but are not limited to, accruals of certain liabilities, including clinical trial accruals and other contingencies, the valuation of financial instruments, the fair value of the Company’s common stock warrants and the fair value of options granted under the Company’s equity incentive plan. On an ongoing basis, the Company evaluates its estimates, including those related to the fair values of assets, stock-based compensation, clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ materially from these estimates.
Emerging Growth Company and Smaller Reporting Company Status
The Company is currently an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”) and may take advantage of reduced reporting requirements that are otherwise applicable to public companies. Section 107 of the JOBS Act exempts emerging growth companies from complying with new or revised financial accounting standards until private companies are required to comply with those standards. The Company has elected to use the extended transition period for complying with new or revised accounting standards. The Company will lose its status as an emerging growth company status as of December 31, 2026, the last day of the fiscal year following the fifth anniversary of the closing of its IPO in August 2021.
The Company is also a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act. If the Company is a smaller reporting company at the time the Company ceases to be an emerging growth company, the Company may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, the Company may choose to present only the two most recent fiscal years of audited financial statements in its Annual Report on Form 10-K and, like emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
From time to time, new accounting pronouncements are issued by the FASB or other standard-setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position or results of operations upon adoption.
Recently Issued and Adopted Accounting Pronouncements
There were no new accounting pronouncements that were issued or became effective since the issuance of the 2025 Annual Report that had, or are expected to have, a material impact on our unaudited condensed balance sheets, unaudited condensed statement of operations or unaudited condensed statement of cash flows.
The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on the Company’s condensed interim financial statements.
8
3. Inventory
Inventory as of September 30, 2026 and December 31, 2025 at $
4. Property and Equipment, Net
Property and equipment, net are as follows (in thousands):
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Property and equipment |
|
$ |
|
|
$ |
|
||
Subtotal |
|
|
|
|
|
|
||
Less accumulated depreciation |
|
|
( |
) |
|
|
( |
) |
Property and equipment, net |
|
$ |
|
|
$ |
|
||
During the nine months ended September 30, 2026, the Company purchased approximately $
Depreciation is computed on a straight-line basis over the estimated useful lives of the assets. The useful life for furniture and equipment is
Depreciation expense for the nine months ended September 30, 2026, was approximately $
5. Accrued Expenses
The components of accrued expenses are as follows (in thousands):
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Employee benefits |
|
$ |
|
|
$ |
|
||
Clinical trial |
|
|
|
|
|
|
||
Current portion of operating lease liability |
|
|
|
|
|
|
||
Other |
|
|
|
|
|
|
||
Total accrued expenses |
|
$ |
|
|
$ |
|
||
6. Fair Value Measurements
As of September 30, 2026 and December 31, 2025, the Company held cash equivalents of $
The following tables summarize the Company’s financial assets and liabilities, measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):
9
|
|
Fair Value Measurements at September 30, 2026 using: |
|
|||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total cash equivalents |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Common stock warrant liability |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total liabilities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
|
|
Fair Value Measurements at December 31, 2025 using: |
|
|||||||||||||
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Total |
|
||||
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Money market funds |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total cash equivalents |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Common stock warrant liability |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Total liabilities |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
There were no transfers between Level 1, Level 2 or Level 3 during the periods presented. The Company had no other financial assets or liabilities that were required to be measured at fair value on a recurring basis.
Common Stock Warrants Liability, Changes on Level 3 Liabilities Measured at Fair Value on a Recurring Basis
The following table reflects the change in the Company’s Level 3 common stock warrant liability for the nine months ended September 30, 2026 (in thousands):
Fair value as of December 31, 2025 |
|
$ |
|
|
Change in fair value |
|
|
|
|
Fair value as of September 30, 2026 |
|
$ |
|
The Company remeasures the fair value of its common stock warrant liability at each reporting date. The fair value of the common stock warrants was determined using a probability weighted scenario method with a Monte Carlo simulation and Black-Scholes model. The scenario-based method estimates the fair value of the Company’s common stock warrants by considering various outcomes as assessed by the Company. Quantitative elements associated with the inputs impacting the fair value measurement of the common stock warrants include the underlying fair value of common stock, timing of the expected scenarios, risk-free rate, and volatility of the Company’s shares. The risk-free rate is determined by reference to the U.S. Treasury yield curve for the respective time periods based on the remaining contractual term of the warrants. The volatility is based on the historical volatility of the Company’s stock. The Monte Carlo simulation projects the Company’s volume weighted average stock price based on the various fundamental transaction scenarios considered and utilizes a Black-Scholes model to value the warrants within these scenarios.
The following table details the assumptions used in the Monte Carlo simulation to estimate the fair value of the common stock warrant liability:
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Stock price |
|
$ |
|
|
$ |
|
||
Expected volatility |
|
|
|
|
||||
Expected term (years) |
|
|
|
|
||||
Risk-free interest rate |
|
|
|
|
||||
Dividend rate |
|
|
|
|
||||
The Company had no other financial assets or liabilities that were required to be measured at fair value on a recurring basis.
10
7. Leases, Commitments and Contingencies
Operating Leases
On April 1, 2026, the Company terminated its existing lease agreement, without penalty, and entered into a
Classification of the Company’s operating lease on the condensed balance sheets are as follows (in thousands):
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Assets |
|
|
|
|
|
|
||
Right-of-use operating asset |
|
$ |
|
|
$ |
|
||
Liability |
|
|
|
|
|
|
||
Operating lease liability – current |
|
|
|
|
|
|
||
Operating lease liability – noncurrent |
|
|
|
|
|
|
||
Total liability |
|
$ |
|
|
$ |
|
||
The current operating lease of $
Lease expense and cash paid by lease type that was recognized during the three and nine months ended September 30, 2026 and 2025 are as follows (in thousands):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Operating lease |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Short-term lease |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total lease expense |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
The minimum lease payments are expected to be as follows for the years ending December 31, (in thousands):
Remainder of 2026 |
|
$ |
|
|
2027 |
|
$ |
|
|
2028 |
|
|
|
|
Total lease payments |
|
$ |
|
|
Less imputed interest |
|
|
( |
) |
Present value of operating lease liability |
|
$ |
|
The interest rate implicit in lease contracts is typically not readily determinable and as such, the Company uses its incremental borrowing rate of
Commercial Supply Agreement
The Company entered into a Supply Agreement with Medical Murray, Inc., the Company’s primary third-party RenovoCath manufacturer ("Medical Murray"), with an effective date of June 5, 2025. Under the supply agreement, the Company has agreed to purchase certain minimum order quantities of the Company’s RenovoCath device, based on issued purchase orders modified for limited cancellations or delays as provided in the supply agreement. The Company recognizes the release of RenovoCath devices from Medical Murray as finished goods and records as inventory.
11
The supply agreement has an initial three-year term, with an automatic one-year renewal unless either party provides written notice of termination at least 30 days prior to the expiration date. The supply agreement may be terminated by either party in the event of a force majeure, bankruptcy or insolvency of the other party, and uncured material breach. The Company may terminate the supply agreement if RenovoCath is withdrawn or suspended by a government authority. In addition, either party may terminate for convenience with one-year written notice. In the event of early termination, the Company is obligated to pay the shortfall commitment as of the date of termination.
As of September 30, 2026, the value of the Company’s outstanding non-cancellable purchase commitments associated with the supply agreement is approximately $
Warranties
The Company generally provides warranties for its products from manufacturing defects on a limited basis for a period of 60 days to 30 months. During the term of the warranty, if the device fails to operate properly from defects in materials and workmanship, the Company will replace the defective product.
The Company estimates the costs that it may incur under its warranty program based on the number of units sold, historical and anticipated rates of warranty claims, and cost per claim. The Company has experienced minimal warranty claims to date, and significant warranty claims are not expected, and accordingly
Legal Proceedings
From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company was not subject to any material legal proceedings during three and nine months ended September 30, 2026, and no material legal proceedings are subsequently outstanding or pending.
Guarantees and Indemnification
In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its officers and directors. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments that the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company is not currently aware of any indemnification claims. Accordingly, the Company has not recorded any liabilities for these indemnification rights and agreements as of September 30, 2026.
8. Equity Incentive Plan – Stock-Based Compensation Expense
2021 Omnibus Equity Incentive Plan
On July 19, 2021, the Company’s Board of Directors (the “Board”) adopted the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “2021 Plan”). The 2021 Plan, which became effective immediately prior to the closing of the IPO, initially reserved
The Company accounts for stock-based compensation to employees, consultants and non-employee directors in accordance with ASC Topic 718, Compensation – Stock Compensation. The Company estimates the fair value of stock option awards using the Black-Scholes option pricing model on the date of grant using the assumptions in the table below. Stock options granted to employees and consultants generally vest over four years and have a term of ten years. Stock-based compensation expense for stock options is recognized as expense over the requisite service period,
12
which is the vesting period. As the Company has not paid dividends since inception, nor does it expect to pay any dividends for the foreseeable future, the expected dividend yield assumption is zero. The expected volatility is estimated based on the historical stock volatility of the Company’s own common stock over a period equal to the expected term of the options including by taking the average historic price volatility for industry peers, consisting of several public companies in the Company’s industry that are either similar in size, stage, or financial leverage, over a period equivalent to the expected term of the awards. The risk-free rate of the stock options is based on the U.S. Treasury rate in effect at the time of grant for the expected term of the stock options.
On April 16, 2026, the Board approved an amendment to the 2021 Plan to add
A summary of the stock option activity for the nine months ended September 30, 2026 is as follows:
|
|
Number of |
|
|
Weighted- |
|
|
Weighted- |
|
|
Aggregate |
|
||||
Outstanding as of December 31, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Granted |
|
|
|
|
$ |
|
|
|
- |
|
|
$ |
- |
|
||
Exercised |
|
|
( |
) |
|
$ |
|
|
|
- |
|
|
$ |
- |
|
|
Forfeited |
|
|
( |
) |
|
$ |
|
|
|
- |
|
|
$ |
- |
|
|
Expired |
|
|
|
|
$ |
|
|
|
- |
|
|
$ |
- |
|
||
Outstanding as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Exercisable as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Vested and expected to vest as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
As of September 30, 2026, there was $
For the nine months ended September 30, 2026 and 2025, the Company utilized the Black-Scholes option-pricing model for estimating the fair value of the stock option granted. The Company estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:
|
|
Nine Months Ended September 30, |
|
|||
|
|
2026 |
|
2025 |
|
|
Expected volatility |
|
|
|
|||
Expected term (years) |
|
|
|
|||
Risk-free interest rate |
|
|
|
|||
Dividend rate |
|
|
|
% |
||
The following table summarizes the components of stock-based compensation expense recognized in the Company’s Condensed Statements of Operations during the three and nine months ended September 30, 2026 and 2025 (in thousands):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Research and development |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Total stock-based compensation expense |
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
||||
13
Restricted Stock Units and Restricted Stock Awards Issued for Services
Restricted stock units (“RSU”) are valued based on the closing price of the Company’s common stock on the date of the grant. The fair value of RSU is recognized and amortized on a straight-line basis over the requisite service period of the award.
A summary of the restricted stock units activity for the nine months ended September 30, 2026 is as follows:
|
|
Shares |
|
|
Weighted- |
|
||
Outstanding as of December 31, 2025 |
|
|
|
|
$ |
|
||
Granted |
|
|
|
|
$ |
|
||
Vested |
|
|
( |
) |
|
$ |
|
|
Forfeited |
|
|
|
|
$ |
|
||
Outstanding as of September 30, 2026 |
|
|
|
|
$ |
|
||
|
|
|
|
|
|
|
||
As of September 30, 2026, there was $
The compensation expense is allocated on a departmental basis, based on the classification of the option holder. No income tax benefits have been recognized in the statements of operations and comprehensive loss for stock-based compensation arrangements.
9. Common Stock Warrants
On March 17, 2026, the Company entered into a securities purchase agreement (the “March 2026 Securities Purchase Agreement”) in connection with a private placement offering by the Company (the “March 2026 Offering”) to
Pursuant to the March 2026 Securities Purchase Agreement, in connection with the March 2026 Offering, the Company sold to the Investors an aggregate of: (i)
During August and September 2026, given a rise in the prevailing market prices for the Company's common stock, outstanding warrants to purchase an aggregate of
In April 2026, the April 2024 two-year Series B warrants to purchase up to an aggregate of
14
The following table is a summary of the common stock warrants activity during the nine months ended September 30, 2026.
|
|
Shares |
|
|
Weighted- |
|
|
Weighted- |
|
|
Aggregate |
|
||||
Outstanding as of December 31, 2025 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Issued in March 2026 to: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Milestone Warrants |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
Pre-funded Warrants |
|
|
|
|
$ |
|
|
|
- |
|
|
|
|
|||
Exercise |
|
|
( |
) |
|
$ |
|
|
|
- |
|
|
$ |
( |
) |
|
Expired |
|
|
( |
) |
|
$ |
|
|
|
- |
|
|
$ |
( |
) |
|
Outstanding as of September 30, 2026 |
|
|
|
|
$ |
|
|
|
|
|
$ |
|
||||
10. Income Taxes
The Company had
The Company’s policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. For the nine months ended September 30, 2026 and 2025, the Company had
11. Net Loss Per Share
Basic and diluted net loss per share of common stock was calculated as follows (in thousands except per share amounts):
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Numerator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
Denominator: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Weighted average shares used in computing net loss per share – basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss per share – basic and diluted |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
|
$ |
( |
) |
For the three and nine months ended September 30, 2026 and 2025, the Company had a net loss and as such, all outstanding shares of potentially dilutive securities were excluded from the calculation of diluted net loss per share as the inclusion would be anti-dilutive.
Potentially dilutive securities not included in the computation of diluted net loss per share because to do so would be antidilutive are as follows (in common stock equivalent shares):
|
|
As of September 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Options to purchase common stock |
|
|
|
|
|
|
||
Unvested restricted stock units |
|
|
|
|
|
|
||
Common stock warrants |
|
|
|
|
|
|
||
Total |
|
|
|
|
|
|
||
15
12. Segment Information
Operating segments are defined as components of an entity for which separate financial information is available and that is regularly reviewed by the chief operating decision maker (the "CODM") in deciding how to allocate resources to an individual segment and in assessing performance. The Company operates as a single reporting segment, focused on developing novel targeted oncology therapies and offering RenovoCath delivery system as stand-alone device targeting high unmet medical needs. The Company’s measure of segment profit or loss is net loss. The CODM is the Company's Chief Executive Officer (the "CEO"). The CODM manages and allocates resources to the operations of the Company on a total company basis. Managing and allocating resources on a company basis enables the CEO to assess the overall level of resources available and how to best deploy these resources across functions, clinical, manufacturing and research and development projects that are in line with the Company’s long-term company-wide strategic goals. Consistent with this decision-making process, the CEO uses financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. Operating expenses are used to monitor budget versus actual results. The CODM also uses net loss in competitive analysis by benchmarking to the Company’s peer group. The competitive analysis along with the monitoring of budgeted versus actual results are used in assessing performance of the segment. All the Company’s assets are held in the United States and all the Company’s revenues are derived from the United States.
The following table is representative of revenue and significant expense categories regularly provided to the CODM when managing the Company’s single reporting segment (in thousands):
|
|
Three Months Ended September 30, |
|
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
|
2026 |
|
|
2025 |
|
||||
Revenues |
|
$ |
|
|
$ |
|
|
|
$ |
|
|
$ |
|
||||
Program expenses (1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Clinical trial studies(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Manufacturing, RenovoCath |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other research and development expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Non-program expenses (2) |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Personnel compensation and related expenses, including share-based compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other segment items (3) |
|
|
|
|
|
( |
) |
|
|
|
|
|
|
( |
) |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
$ |
( |
) |
|
$ |
( |
) |
|
|
$ |
( |
) |
|
$ |
( |
) |
Major Customers
For the three and nine months ended September 30, 2026, four cancer center customers for the Company's RenovoCath device, (referred to for these purposes as Customers A, B, C, and D) each accounted for more than
For the three and nine months ended September 30, 2025, five cancer center customers for the Company's RenovoCath device (referred to for these purposes as Customers A, B, C, D, and E) each accounted for more than
16
months ended September 30, 2025, Customers A, B, C, and E accounted for approximately
13. Related Party Transactions
Dr. Ramtin Agah has served as the Company’s Chief Medical Officer and Co-Founder since December 2009, as Chairman of the Board since May 2018. In January 2018, the Company entered into a consulting agreement with Dr. Agah pursuant to which Dr. Agah provides monthly consulting services as the Company’s Chief Medical Officer by overseeing Company-sponsored clinical trials. Since 2018, the Company has amended Dr. Agah’s consulting agreement and may, in the Company’s discretion, proportionally adjust the monthly consulting fee if Dr. Agah’s time commitment increases or decreases. The consulting agreement may be terminated by either party on 30 days’ notice. The consulting agreement amendment also provides for Dr. Agah’s eligibility for an annual target cash incentive bonus equal to
On March 24, 2026, the Board appointed Dr. Agah to the newly created position of Executive Chairman, effective February 27, 2026. In connection with his roles as Chief Medical Officer and Executive Chairman, Dr. Agah accepted an offer letter from the Company on the same date (the “Agah Offer Letter”) to amend, restate and replace certain Consulting Agreement, dated January 1, 2018, between Dr. Agah and the Company. Dr. Agah acknowledged that certain Amended and Restated Change in Control and Severance Agreement, dated November 10, 2025, between the Company and Dr. Agah, remained in full force and effect.
17
Item 2: Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed interim financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q, our management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2025, which is included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026 (as amended, the “2025 Annual Report”).
This discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that reflect our plans, estimates, and beliefs that involve risks and uncertainties, including those described in the section of this Report titled “Cautionary Note Regarding Forward-Looking Statements.” Our actual results and the timing of selected events could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those set forth under the section titled “Risk Factors” included elsewhere in this filing and in the 2025 Annual Report.
Unless the context otherwise requires, all references in this section to the “Company,” “we,” “us,” or “our” refer to RenovoRx, Inc
As used herein, the term “common stock” refers to our common stock, par value $0.0001 per share.
Overview
We are a life sciences company commercializing RenovoCath®, a novel, FDA-cleared device for local drug delivery designed to address significant unmet medical needs, with a focus on difficult-to-treat tumors. We are also evaluating intra-arterial gemcitabine (known as "IAG”) delivered via RenovoCath using RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) platform as a novel drug-device product candidate for difficult-to-treat locally advanced pancreatic cancer ("LAPC").
Our patented TAMP platform, utilizing RenovoCath, is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor locally, while potentially minimizing a therapy’s toxicities versus systemic intravenous chemotherapy. Our novel approach to targeted drug-delivery offers the potential for improved efficacy, safety, and tolerability, and our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of therapeutic agents.
In the third quarter of 2026, we continued to strengthen our intellectual property position. In August 2026, the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering RenovoCath dual-occlusion catheter system, bringing our portfolio to 10 issued or allowed (1 allowed) US patents, 10 issued OUS patents, 6 pending US cases, 7 pending OUS cases and 2 pending Patent Cooperation Treaty (PCT) applications.
Commercialization of RenovoCath
Until 2025, we primarily focused our efforts on progressing our novel drug-device combination oncology product candidate, IAG delivered via RenovoCath, through our ongoing Phase III TIGeR-PaC study for LAPC. IAG is currently under investigation and has not been approved for commercial sale. IAG received Orphan Drug Designation ("ODD") for pancreatic cancer and bile duct cancer, which provides seven years of market exclusivity upon new drug application approval by the FDA. In the second quarter of 2026, we were granted an additional ODD for oxaliplatin for the treatment of pancreatic cancer.
As the TIGeR-PaC study progressed, we received unsolicited (and subsequently solicited) feedback from oncologists, surgeons, and interventional radiologists highlighting strong interest in our technology, indicating a demand and commercial opportunity for targeted delivery of diagnostic and/or therapeutic agents. As a result, during the first half of 2024, we began to actively explore a new opportunity to market and sell RenovoCath as a standalone medical device. We launched this effort with relatively little capital outlay, and in December 2024, we announced our first commercial purchase orders for RenovoCath devices with more than ten medical institutions initiating the purchasing process, while in discussions with more than twenty additional institutions.
18
We are actively commercializing the TAMP platform and RenovoCath as a stand-alone device. TAMP , enabled by RenovoCath, is a collaborative, localized drug-delivery platform, with two ways emerging therapies can strengthen our opportunity: (i) TAMP can deliver established drugs locally sequentially to or concurrently with novel therapies, creating the potential for improved patient outcomes, concentrating therapy where it is needed, and (ii) as new drugs come to market, we believe many of these drugs can be delivered directly via our RenovoCath device. And in both cases, we believe that novel improved therapies could make the TAMP targeted drug-delivery platform even more valuable.
During the third quarter 2026, we generated record revenue of approximately $1.1 million, our strongest quarterly performance to date, increasing approximately 17% sequentially, and nearly 300% or more than four-fold higher year-over-year. Revenue for the first nine months of 2026 was approximately $2.5 million, more than double our full year 2025 revenue of $1.1 million. This is a direct, measurable result of the commercial model we have described. We believe that every new commercial cancer center we activate drives the opportunity for more procedures and revenue, accelerating growth.
Driving much of our growth is our fully staffed sales team that continues to gain traction and accelerate customer engagement and adoption of TAMP. Our sales team is comprised of a Vice President of Sales and Market Development, and five Regional Market Development Managers, is strategically deployed to cover major U.S. cancer centers. Importantly, the activity of our sales team is ramping. We believe our focused and regionally deployed sales team is sufficiently sized to address the market and effectively penetrate cancer centers that treat solid tumors, such as pancreatic cancer.
Our continued strong quarterly performance supports management's belief that our 2026 revenue will exceed our original full-year forecast. This outlook is driven by more active commercial cancer center customers, more patients treated via procedures with RenovoCath, and repeat ordering across our existing customer base. As physicians incorporate RenovoCath into routine clinical practice, repeat utilization is expected to drive sustained revenue growth. Based on its current customer pipeline and trends to date, we remain on target to deliver full year 2026 revenue in the range of $3.75 million to $4.25 million. This expectation is based on the current customer utilization trends, customer activation timelines, repeat ordering patterns and management’s assumptions regarding customer adoption and utilization rates.
We define "active" commercial cancer centers as centers where doctors are actively treating patients with RenovoCath. Management believes active commercial cancer centers is a useful operating metric because it reflects sites that are capable of generating revenue-producing procedures and provides insight into future utilization trends and recurring revenue opportunities.
We ended the third quarter of 2026 with 26 active commercial cancer center customers, compared to 21 at the end of the second quarter of 2026. We remain confident in our ability to meet the year-end 2026 target of 36 active commercial cancer centers as we continue to activate centers in the commercial funnel and convert sites from its fully enrolled Phase III TIGeR-PaC trial to active centers.
In the third quarter of 2026, we continued to support building the evidence base for TAMP through a multi-center post-marketing registry study to generate real-world safety and efficacy data, as well as supporting Investigator Initiated Trials (IITs) in borderline resectable and metastatic pancreatic cancer and cholangiocarcinoma (bile duct cancer). These studies are designed to achieve cost neutrality while broadening the platform’s evidence base. See “Clinical Research and Scientific Programs” below for further information.
In August 2026, TAMP enabled by RenovoCath was deployed in the first commercial clinical use in a solid tumor beyond pancreatic cancer as an existing commercial cancer center customer utilized the device to treat a patient with sarcoma. The Company views this physician-driven expansion as an encouraging indicator of the potential for broader adoption of RenovoCath within its FDA-cleared fields of use.
We continue to estimate that the initial total addressable market (TAM) for RenovoCath as a stand-alone device could translate into an approximately $400 million peak annual U.S. sales opportunity for RenovoRx. Over time, as we expand the platform into additional solid tumor indications, we believe it could unlock more than $1 billion in peak annual sales potential.
19
Clinical Research and Scientific Programs
We are evaluating IAG delivered via RenovoCath in the ongoing Phase III TIGeR-PaC clinical trial for the treatment of LAPC. IAG is being studied under a U.S. investigational new drug (IND) study regulated by the FDA's Center for Drug Evaluation and Research (CDER) pursuant to 21 CFR Part 312. IAG utilizes RenovoCath, which is FDA-cleared for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
In August 2026, we achieved full enrollment in the TIGeR-PaC trial. This significant milestone reflects successful patient recruitment, clinical execution, and collaboration among investigators and study teams evaluating IAG for LAPC, a difficult-to-treat cancer. The primary endpoint of the study is overall survival. TIGeR-PaC is designed to evaluate whether our patented method of targeted delivery of the chemotherapy gemcitabine improves patient survival, safety, and tolerability compared to the standard of care, systemic (intravenous) chemotherapy gemcitabine + Abraxane.
We anticipate initial top-line data from TIGeR-PaC in the second half of 2027, and expect the data readout to support and potentially expand current clinical adoption of TAMP by providing more rigorous evidence on tolerability and reduced side effects. The trial may also show whether TAMP can improve survival in this setting.
Pancreatic cancer continues to represent a major unmet medical need, with limited treatment options and current standards of care centered largely on systemic chemotherapy, which can cause significant toxicity and related side effects for patients. TAMP is designed to deliver therapy directly near the tumor site while potentially reducing systemic exposure.
More specifically, TIGeR-PaC is studying the intra-arterial ("IA") administration of gemcitabine to treat LAPC following stereotactic body radiation therapy (“SBRT”). The study compares the treatment of LAPC using IA delivery of gemcitabine with RenovoCath versus systemic, standard of care, intravenous (i.e., systemic) administration of gemcitabine and nab-paclitaxel. Our protocol for TIGeR-PaC involves systemic chemotherapy and SBRT during the induction phase of the study (prior to randomization). In December 2021, we amended our protocol and statistical analysis plan for TIGeR-PaC (the “Modified SAP”) to (i) enroll and analyze only patients receiving SBRT during the induction phase, (ii) include a second interim analysis, (iii) change the total number of patients randomized in the study to 114 with a total of 86 events (deaths) from SBRT patients required to complete the final analysis, and (iv) repower the study from 90% to 80%. The change to the 80% power calculation aligns with common practice for clinical trials and we believe this design will shorten the timeframe needed to complete the study, as well as significantly decrease its cost. We have not discussed the protocol amendment or the Modified SAP with the FDA, and we cannot provide any assurance that the FDA will agree with these modifications, but these modifications have been submitted to the FDA.
The first interim analysis in the Phase III TIGeR-PaC study at the 26th event (death) of the specified events was completed in March 2023, with the study's DMC recommending a continuation of the study. The interim analysis showed a 6-month median overall survival benefit for IAG patients (nearly a 60% improvement) versus the study control arm patients treated with current standard of care. Patients also had greater than 65% reduction in adverse events with RenovoCath with gemcitabine vs. standard of care.
In terms of our IIT's, in October 2026, the first patient was treated in PRISM-TAMP, an IIT led by researcher at the University of Vermont (UVM). The trial is evaluating gemcitabine delivered through the TAMP platform, enabled by RenovoCath, before surgery in patients with planned surgical resection for the first time in the neoadjuvant setting. It is the first IIT supported by RenovoRx to begin patient enrollment and takes TAMP upstream of locally advanced disease, where physicians have asked about its potential. UVM plans to enroll approximately 10 patients in this trial. IITs are capital-efficient for the Company and allow independent investigators to generate safety and tolerability data for new applications of TAMP.
During the third quarter and the subsequent period, we added clinical evidence supporting its TAMP platform, including two peer-reviewed publications:
20
Cash Resources, History of Losses and Planned Activities
We have incurred significant operating losses and generated negative cash flows from operations since our inception. As of September 30, 2026, we had cash and cash equivalents of $10.4 million. We reported net losses of $3.6 million and $10.1 million for the three and nine months ended September 30, 2026, respectively. As of September 30, 2026, we had an accumulated deficit of $71.5 million. We expect to continue to incur significant expenses, operating losses and negative cash flows while we seek to grow our revenues from RenovoCath commercial sales and work towards our goal of cashflow positive operations. We will not generate revenues from IAG sales unless and until we successfully complete development, obtain regulatory approval for, and commercially launch IAG. Given economic and market conditions and timing of regulatory approval, we expect that our expenses will increase in connection with our ongoing commercial, research and development activities, particularly if and when we decide to:
In addition to the variables described above, if and when IAG or any of our other potential future product candidates successfully complete development and receive regulatory approval, we will incur substantial additional costs associated with establishing a sales, marketing, medical affairs and distribution infrastructure to commercialize IAG or other products for which we may obtain marketing approval, regulatory filings, marketing approval, and post-marketing requirements, and other commercial costs. We cannot reasonably estimate these costs at this time.
Due to our recurring operating losses and the expectation that we will continue to incur net losses in the future, there is a risk that we will be required to raise additional capital at some point to continue the commercialization of RenovoCath and complete the development of and gain regulatory approval for IAG or any other of our future potential product candidates. We have historically financed our operations primarily through private and public sales of our equity (including warrants to purchase common stock). To raise additional capital, we may seek to sell additional equity and/or debt securities, obtain a credit facility or other loan or enter into collaborations, licenses or other similar arrangements, which we may not be able to do on favorable terms, or at all.
Our ability to obtain additional financing will be subject to a number of factors, including market conditions, fluctuations in interest rates, our operating performance and investor sentiment. If we are unable to raise additional
21
capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our product candidates, restrict or cease our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional capital on acceptable terms, or at all, would result in a material and adverse impact on our operations.
Our condensed interim financial statements as of September 30, 2026, have been prepared on a going concern basis and do not include any adjustments that may result from the outcome of this uncertainty. Based on our operating plans, we expect that our current cash and cash equivalents as of the date of this Report will be sufficient to fund our operating, investing and financing cash flow needs at least the next 12 months from the date of issuance of this report (i.e., into the second half of 2027), assuming our commercial strategy and our development programs advance as currently contemplated.
As a result, while raising capital is not our current focus, we may require additional funding in the future to support our strategy. Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through private or public equity financings (including potential exercises of outstanding common stock purchase warrants), debt financings and collaborations, licensing agreements or other similar arrangements. We currently have no credit facility or committed sources of capital. To the extent that we raise additional capital through equity or debt, the ownership interests of our stockholders will be diluted and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that could restrict our operations. We may require additional capital beyond our currently anticipated amounts and additional capital may not be available on reasonable terms, or at all. If we raise additional funds through collaboration arrangements or other strategic transactions in the future, we may have to relinquish valuable rights to our technologies or future revenue streams or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through private or public equity financings or debt financings when needed, we may be required to delay, limit, reduce or terminate development or future commercialization efforts, and we may be unable to continue as a going concern. If we are unable to continue as a going concern, we might have to liquidate our assets and the value we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our condensed interim financial statements, and our shareholders may lose their entire investment in our common stock.
Components of Our Results of Operations
Revenue
In the fourth quarter of 2024, we began generating revenue through the sale of our RenovoCath device on a standalone basis directly to end user customers (i.e., hospitals and cancer treatment centers), and revenue generation from such activity continued for the entire year ended December 31, 2025 and accelerated during the nine months ending September 30, 2026, with the third quarter of 2026 being a record revenue quarter for us. We consider customer purchase orders, which in some cases are governed by master sales agreements or standard terms and conditions, to be the contracts with a customer. Our contracts with customers typically contain a single performance obligation, which is the delivery of the RenovoCath device. We recognize revenue from sales of products at the point in time that the customer obtains control, which is typically based upon the terms of delivery. In determining the transaction price, we evaluate whether the price is subject to refund or adjustment to determine the net consideration to which we expect to be entitled. The only type of variable consideration we offer is limited return rights relating primarily to product damage or defects identified upon receipt, and therefore we expect minimal returns. Returns are estimated taking into consideration several factors including these limited product return rights, historical return activity, and other relevant factors. As of September 30, 2026 and December 31, 2025, we recorded nil of allowance for returns.
Cost of Revenue
Cost of revenue consists of costs associated with the sales of RenovoCath devices primarily from Medical Murray, our third-party RenovoCath manufacturer. Prior to the commercialization of RenovoCath, all costs of manufacturing to produce the RenovoCath devices were allocated to our TIGeR-PaC Phase III clinical trial study in prior periods and expensed as research and development. The cost for RenovoCath devices not associated with the TIGeR-PaC study represents primarily third-party manufacturing costs and shipping and handling costs when applicable.
Operating Expenses
22
Research and Development
Research and development expenses consist of costs related to the research and development of our TAMP technology and our ongoing clinical trial. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors and consultants. We outsource a substantial portion of our clinical trial activities, having utilized the services of third-party clinical trial sites and contract research organizations to assist us with the execution of our clinical trials. In addition, we have FDA 510(k) clearance for the RenovoCath delivery device, which comprises part of our IAG product candidate. Accordingly, we are able to charge our clinical trial sites for the RenovoCath delivery device. To date, payments from clinical trial sites in consideration for RenovoCath delivery devices have been adequate to cover our direct manufacturing costs. Any payments we receive from clinical trial sites as consideration for use of RenovoCath delivery devices offset our research and development expenses. We expect our research and development expenses to increase for the foreseeable future as we continue the development of our product candidates, initiate other new clinical trials, post marketing study (what we call our RR5 study) and IITs studies, and pursue regulatory approval of our product candidates. It is difficult to predict with any certainty the duration and costs of completing our current or future clinical trials of our product candidates or if, when or to what extent we will achieve regulatory approval and generate revenue from the commercialization and sale of our product candidates. The duration, costs and timing of clinical trials and other development of our product candidates will depend on a variety of factors, including uncertainties in clinical trial enrollment, timing and extent of future clinical trials, development of new product candidates and significant and changing government regulation. We may never succeed in achieving regulatory approval for any of our product candidates.
Our research and development expenses include:
Research and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials and animal studies, are recognized based on evaluation of progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to us by third party vendors.
Selling, General and Administrative
Selling, general and administrative expenses consist of salaries, benefits, and stock-based compensation for personnel in executive, finance and administrative functions, professional services and associated costs related to accounting, tax, audit, legal, intellectual property and other matters, consulting costs, marketing, conferences, travel and allocated expenses for rent, insurance and other general overhead costs. We expect to continue to incur additional expenses as a result of operating as a public company, including costs to comply with the rules and regulations of the SEC, and Nasdaq continued listing standards and increased expenses in the areas of insurance, professional services and investor
23
relations. As a result, we expect our selling, general and administrative expenses to increase in the foreseeable future. Selling, general and administrative expenses are expensed as incurred.
Other Income (Expense), Net
Interest Income, Net
Interest expense consists of expense for the amortization of directors and officers liability insurance premiums.
Interest income is earned from cash deposited in our short-term marketable securities and money market account.
Change in Fair Value of Warrant Liability
Change in fair value of warrant liability represents the gain or loss reported from the change in the fair value of the common stock warrant liability for warrants issued in our April 2023 registered direct offering.
Income Tax Expense
We account for income taxes using the asset and liability method. Under this method, deferred income tax assets and liabilities are recorded based on the estimated future tax effects of differences between the financial statement and income tax basis of existing assets and liabilities. Deferred income tax assets and liabilities are recorded net and classified as noncurrent on the balance sheets. A valuation allowance is provided against our deferred income tax assets when their realization is more likely than not.
We are subject to income taxes in the federal and state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. In accordance with the authoritative guidance on accounting for uncertainty in income taxes, we recognize tax liabilities for uncertain tax positions when it is more likely than not that a tax position will not be sustained upon examination and settlement with various taxing authorities. Liabilities for uncertain tax positions are measured based upon the largest amount of benefit that is more-likely-than-not (greater than 50%) of being realized upon settlement. Our policy is to recognize interest and/or penalties related to income tax matters in income tax expense.
Results of Operations
Comparison of the Three Months Ended September 30, 2026 and 2025
The following table summarizes the significant components of our results of operations for the periods presented (in thousands, except percentages):
24
|
|
Three Months Ended September 30, |
|
|
Increase / (Decrease) |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
$ |
|
|
% |
|
||||
|
|
(unaudited) |
|
|
|
|
|
|
|
|||||||
Revenues |
|
$ |
1,066 |
|
|
$ |
266 |
|
|
$ |
800 |
|
|
|
301 |
|
Cost of revenues |
|
|
188 |
|
|
|
53 |
|
|
|
135 |
|
|
|
255 |
|
Gross profit |
|
|
878 |
|
|
|
213 |
|
|
|
665 |
|
|
|
312 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
1,241 |
|
|
$ |
1,685 |
|
|
$ |
(444 |
) |
|
|
(26 |
) |
Selling, general and administrative |
|
|
2,873 |
|
|
|
1,728 |
|
|
|
1,145 |
|
|
|
66 |
|
Total operating expenses |
|
|
4,114 |
|
|
|
3,413 |
|
|
|
701 |
|
|
|
21 |
|
Loss from operations |
|
|
(3,236 |
) |
|
|
(3,200 |
) |
|
|
(36 |
) |
|
|
(1 |
) |
Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest and dividend income |
|
|
76 |
|
|
|
113 |
|
|
|
(37 |
) |
|
|
(33 |
) |
Loss on disposition of asset |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(100 |
) |
Change in fair value of common warrant liability |
|
|
(487 |
) |
|
|
175 |
|
|
|
(662 |
) |
|
|
(378 |
) |
Total other income (expense), net |
|
|
(411 |
) |
|
|
288 |
|
|
|
(699 |
) |
|
|
(243 |
) |
Net loss |
|
$ |
(3,647 |
) |
|
$ |
(2,912 |
) |
|
$ |
(735 |
) |
|
|
(25 |
) |
Revenue
We recognized record quarterly revenue of approximately $1.1 million from sales of RenovoCath for the three months ended September 30, 2026, compared to $0.3 million for the same period last year, representing a $0.8 million increase in sales volume. The growth was driven by continued expansion of active commercial cancer centers and repeat ordering from our existing commercial cancer center base. We expect to continue to grow revenue from RenovoCath sales.
Cost of Revenue
Cost of revenue was approximately $0.2 million for the three months ended September 30, 2026, compared to approximately $53,000 cost of revenue for the same period last year, an increase of $0.1 million due to additional sales compared to the prior period last year. We expect costs of revenue to increase as we increase our revenue from RenovoCath sales.
Research and Development
Research and development expenses were approximately $1.2 million for the three months ended September 30, 2026, compared to $1.7 million for the same period last year, a decrease of $0.5 million. The period-over-period decrease in research and development expenses is primarily driven by a decrease in regulatory and clinical consulting expenses of $0.5 million due to costs associated with our ongoing TIGeR-PaC trial, including a decrease of $0.2 million in selling, general, and administrative overhead expenses allocated to research and development expense. This decrease was off-set by an increase in employees and related benefit costs of $0.2 million. We anticipate research and development expenses to continue to increase for the remainder of 2026 and into the first half of 2027 as we advance our clinical development of IAG and the development of our next generation RenovoCath device including incurring expenses for the filing of a 510(k) with the FDA next year at least 90 days before the device is offered for sale.
Selling, General and Administrative
Selling, general and administrative expenses were approximately $2.9 million for the three months ended September 30, 2026, compared to $1.7 million for the same period last year, an increase of approximately $1.2 million. The period-over-period increase in selling, general and administrative expenses is primarily driven by an increase in head count and employee and related benefit costs of $0.8 million including an increase in marketing and travel related expenses of $0.2 million as we made targeted investments in expanding our RenovoCath commercialization program, resulting in an increased commercial pipeline, additional active cancer center customers and increase in revenue. In addition, selling, general, and administrative overhead expenses allocated to research and development expenses
25
decreased by $0.2 million, offset by a decrease in professional and other expenses of $0.1 million. We anticipate selling, general and administrative expenses to continue to increase as we progress with our commercialization activities for RenovoCath.
Other Income (Expense), Net
Other expense was approximately $0.4 million for the three months ended September 30, 2026, compared to other income of approximately $0.3 million for the same period last year. The increase in other expense was primarily due to a $0.7 million change in the fair value of common warrant liability, primarily due to an increase in our stock price.
Comparison of the Nine Months Ended September 30, 2026 and 2025
|
|
Nine Months Ended September 30, |
|
|
Increase / (Decrease) |
|
||||||||||
|
|
2026 |
|
|
2025 |
|
|
$ |
|
|
% |
|
||||
|
|
(unaudited) |
|
|
|
|
|
|
|
|||||||
Revenues |
|
$ |
2,538 |
|
|
$ |
885 |
|
|
$ |
1,653 |
|
|
|
187 |
% |
Cost of revenues |
|
|
415 |
|
|
|
299 |
|
|
|
116 |
|
|
|
39 |
% |
Gross profit |
|
|
2,123 |
|
|
|
586 |
|
|
|
1,537 |
|
|
|
262 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
$ |
3,669 |
|
|
$ |
4,768 |
|
|
$ |
(1,099 |
) |
|
|
-23 |
% |
Selling, general and administrative |
|
|
8,508 |
|
|
|
4,806 |
|
|
|
3,702 |
|
|
|
77 |
% |
Total operating expenses |
|
|
12,177 |
|
|
|
9,574 |
|
|
|
2,603 |
|
|
|
27 |
% |
Loss from operations |
|
|
(10,054 |
) |
|
|
(8,988 |
) |
|
|
(1,066 |
) |
|
|
-12 |
% |
Other income (expense), net |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Interest and dividend income |
|
|
210 |
|
|
|
352 |
|
|
|
(142 |
) |
|
|
-40 |
% |
Loss on disposition of asset |
|
|
(2 |
) |
|
|
- |
|
|
|
(2 |
) |
|
|
-100 |
% |
Change in fair value of common warrant liability |
|
|
(233 |
) |
|
|
409 |
|
|
|
(642 |
) |
|
|
-157 |
% |
Total other income (expense), net |
|
|
(25 |
) |
|
|
761 |
|
|
|
(786 |
) |
|
|
-103 |
% |
Net loss |
|
$ |
(10,079 |
) |
|
$ |
(8,227 |
) |
|
$ |
(1,852 |
) |
|
|
-23 |
% |
Revenue
We recognized approximately $2.5 million of revenue from sales of RenovoCath for the nine months ended September 30, 2026, compared to $0.9 million for the same period last year, representing a $1.6 million increase in sales volume. The significant growth reflects continued expansion of active commercial cancer centers and increasing procedural utilization of RenovoCath across our active commercial cancer centers. We expect to grow revenue from RenovoCath sales on a sequential quarter-by-quarter basis for the remainder of 2026.
Cost of Revenue
Cost of revenue was approximately $0.4 million for the nine months ended September 30, 2026, compared to approximately $0.3 million, remaining relatively flat for the same period last year. Prior to the Medical Murray supply agreement, devices sold for the same period as last year were manufactured based on time and materials which resulted in higher manufacturing costs per device. We expect costs of revenue to increase as we increase our revenue from RenovoCath sales.
Research and Development
Research and development expenses were approximately $3.7 million for the nine months ended September 30, 2026, compared to $4.8 million for the same period last year, a decrease of $1.1 million. The period-over-period decrease in research and development expenses is primarily driven by a decrease in regulatory and clinical development of $0.9 million due to costs associated with our ongoing Phase III clinical trial study TIGeR-PaC, including a decrease in non-recurring engineering costs for the development of the next generation of our RenovoCath delivery system of $0.1 million, and selling, general, and administrative overhead expenses allocated to research and development costs of $0.6 million. These decreases were offset by an increase in employees and related benefit costs of $0.5 million
26
primarily due to increased headcount and personnel-related expenses. We anticipate research and development expenses to increase for the remainder of 2026 and into the first half of 2027 as we advance our clinical development of IAG and the development of our next generation RenovoCath device including incurring expenses for the anticipated potential filing of a New Drug Application with the FDA for IAG.
Selling, General and Administrative
Selling, general and administrative expenses were approximately $8.5 million for the nine months ended September 30, 2026, compared to $4.8 million for the same period last year, an increase of approximately $3.7 million. The period-over-period increase in selling, general and administrative expenses is primarily driven by an increase in head count and employee and related benefit costs of $2.0 million including an increase in travel and marketing related expenses of $0.5 million as we made targeted investments in expanding our RenovoCath commercialization program, resulting in an increased commercial pipeline, additional active cancer center customers and a resulting increase in revenue. Professional, and other expenses increased $0.6 million, including a decrease in selling, general, and administrative overhead expenses allocated to research and development expenses of $0.6 million. We anticipate selling, general and administrative expenses to increase as we progress with our commercialization activities for RenovoCath.
Other Income (Expense), Net
Other expense was approximately $25,000 for the nine months ended September 30, 2026, compared to other income of approximately $0.8 million for the same period last year. The decrease in other income was primarily due to a $0.6 million change in the fair value of common warrant liability, due to an increase of the warrant liability expense attributed by an increase in our stock price and a decrease in interest income including other miscellaneous expenses of approximately $0.2 million.
Liquidity and Capital Resources
From our inception through September 30, 2026, we had raised an aggregate of $84.9 million, primarily from private placements of convertible preferred stock, convertible debt securities, the issuance of securities in registered and private placement offerings and the exercise of common stock warrants and common stock options. After deducting underwriting discounts and commissions, placement agent fees and other offering expenses, our net proceeds from these offerings were $76.0 million. As of September 30, 2026, we had cash and cash equivalents of $10.4 million.
We have incurred significant losses and negative cash flows from operations since our inception. For the nine months ended September 30, 2026, we recorded a net loss of $10.1 million and an accumulated deficit of $71.5 million. Depending on our commercialization efforts with RenovoCath, we do not expect to generate positive cash flows from operations in the near future, although that is an important goal for our commercial efforts. We also expect to incur losses from our clinical activities until revenues from RenovoCath sales grow and outpace cash and non-cash expenses. Losses may also continue until regulatory approval is granted for our lead product candidate, IAG, and until IAG is commercially launched and revenues are generated from sales of IAG, all of which, with respect to IAG, will not occur for several years. We face the risk that commercial sales of RenovoCath will not grow as anticipated, and regulatory approval of IAG is not guaranteed and may never be obtained. We may also pursue other revenue-generating strategies such as licensing or collaboration agreements. No assurances can be made that we will pursue these strategies, and even if we do, there is a risk that we will be unable to generate revenue from such activities.
We believe we will be able to continue to raise additional required capital as needed through debt financings, private or public equity financings, potential exercises of outstanding warrants, license agreements, collaborative agreements or other arrangements with other companies, or other sources of financing. There can be no assurance that such financing will be available as and when needed or will be at terms acceptable to us. Our inability to raise capital as and when needed would have a negative impact on our liquidity, financial condition and our ability to pursue our business strategy. We will need to generate significant revenue from commercial sales of RenovoCath or otherwise to achieve cashflow positive operations or profitability, and we may never do so. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our clinical trials or other operations. If any of these events occur, our ability to achieve our operational goals would be adversely affected. Our future capital requirements and the adequacy of available funds will depend on many factors, including those described in the section of this Report and our 2025 Annual Report titled “Risk Factors.” Depending on the severity and direct impact of these
27
factors on us, we may be unable to secure additional financing to meet our operating requirements on commercially acceptable terms favorable to us, or at all.
On March 20, 2026, we closed on a private placement offering to 15 accredited investors, of which 5 were insider investors, and issued 8,438,790 shares of common stock, 2,200,000 pre-funded warrants, and 5,319,392 revenue milestone warrants, representing 50% warrant coverage. The revenue milestone warrants have an exercise price equal to two times (2x) the purchase price paid for the shares of common stock in the offer, and they expire on the earlier of: (i) 30 days of our reporting $1.5 million in gross product sales in any fiscal quarter and (ii) March 30, 2029. We raised aggregate gross proceeds of $10.0 million in this financing, before deducting placement agent fees and other legal and professional fees of approximately $0.7 million. In addition, we incurred approximately $0.3 million of issuance costs.
During August and September 2026, given a rise in the prevailing market prices for our common stock, outstanding warrants to purchase an aggregate of 2,858,609 shares of our common stock were exercised for cash by the holders thereof (excluding warrants to purchase 491,923 shares of our common stock that were exercised on a cashless basis). As of September 30, 2026, these common stock warrants exercises generated gross proceeds of approximately $3.5 million.
As of the date of this Report, we believe that we have sufficient cash resources, to allow us to fund our operating, investing and financing cash flow needs through at least the next 12 months (i.e., into the second half of 2027). The accompanying unaudited condensed interim financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying unaudited condensed interim financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if we are unable to continue as a going concern.
Sources of Liquidity
Since our inception, we have been primarily a clinical stage company working on the development of IAG, and our principal sources of liquidity have been for the financing transactions we have undertaken as described above. In 2024, we made the decision to launch an effort to commercialize our RenovoCath device as a standalone product within its FDA-cleared fields of use and upon our initial commercialization launch of RenovoCath, we generated revenue in the fourth quarter of 2024. We have since grown our RenovoCath revenues, and our goal is to grow revenues from our RenovoCath commercialization efforts over time. However, we have incurred significant operating losses and negative cash flows from operations and we anticipate that we will continue to incur net losses until our RenovoCath commercial efforts generate meaningful revenues, of which no assurances can be given.
Cash Flows
Our primary uses of cash are to fund our operations including research and development, commercialization of our RenovoCath as a standalone device and selling, general and administrative expenses. We will continue to incur operating losses in the future and expect that our research and development and selling, general and administrative expenses will continue to increase as we continue our research and development efforts with respect to clinical development of IAG and further develop our technology platform, commercializing RenovoCath and ensuring we are complying with the requirements of being a public company (including following our loss of emerging growth company status as of December 31, 2026). The cash used to fund operating expenses is impacted by the timing of when we pay expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.
28
The following table summarizes our cash flows for the periods indicated (in thousands):
|
|
Nine Months Ended September 30, |
|
|||||
|
|
2026 |
|
|
2025 |
|
||
Net cash provided by (used in): |
|
|
|
|
|
|
||
Operating activities |
|
$ |
(9,115 |
) |
|
$ |
(7,953 |
) |
Investing activities |
|
|
(90 |
) |
|
|
(2 |
) |
Financing activities |
|
|
12,585 |
|
|
|
10,845 |
|
Net increase in cash and cash equivalents |
|
$ |
3,380 |
|
|
$ |
2,890 |
|
Net Cash Used in Operating Activities
Cash used in operating activities for the nine months ended September 30, 2026, reflected a net loss of $10.1 million, offset by non-cash charges of approximately $1.7 million, and a net change in our operating assets and liabilities of $0.7 million.
Cash used in operating activities for the nine months ended September 30, 2025, reflected a net loss of $8.2 million, offset by non-cash charges of $0.6 million, and a net change in our operating assets and liabilities of $0.4 million.
Cash Used in Investing Activities
Cash used in investing activities for the nine months ended September 30, 2026, consisted of $90,000 for the purchase of property and equipment.
Cash used in investing activities for the nine months ended September 30, 2025, consisted of $2,000 for the purchase of property and equipment.
Cash Provided by Financing Activities
Net cash provided by financing activities for the nine months ended September 30, 2026 was $12.6 million, consisting primarily of net proceeds from the March 2026 private placement and proceeds of $3.5 million from warrant exercises in August and September 2026.
Net cash provided by financing activities for the nine months ended September 30, 2025 was $10.8 million, consisting primarily of net proceeds from a registered equity offering.
Contractual Obligations and Other Commitments
In April 2026, we terminated our existing lease agreement for our administrative corporate headquarters without penalty, and entered into a new 33-month non-cancelable operating lease within the same office building, commencing on April 1, 2026 and ending on December 31, 2028. The lease has a one-time option to renew the term for an extension period of 36 months.
In June 2026, we entered into a new non-cancelable purchase commitment of $1.5 million with Medical Murray, our third-party manufacturer, for our RenovoCath device. The purchase commitment will provide commercially available RenovoCath devices for our cancer centers into the second half of 2027.
Critical Accounting Policies and Significant Judgments and Estimates
The accompanying management’s discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed interim financial statements and the related disclosures, which have been prepared in accordance with GAAP. The preparation of these unaudited condensed interim financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our unaudited condensed interim financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.
29
Actual results may differ from these estimates under different assumptions or conditions. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. Our critical accounting policies and estimates are detailed in our 2025 Annual Report.
There have been no significant changes to our critical accounting policies or significant judgments and estimates for the nine months ended September 30, 2026, from those previously disclosed in our 2025 Annual Report.
Convertible Instruments and Embedded Derivatives
We evaluate all of our agreements to determine whether such instruments have derivatives or contain features that qualify as embedded derivatives. We account for certain redemption features that are associated with the terms of convertible notes as liabilities at fair value and adjust the instruments to their fair value at the end of each reporting period. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in other income (expenses), net in the statements of operations. Derivative instrument liabilities are classified in the balance sheets as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.
Pre-Funded Common Stock Warrants and Common Stock Warrants
We evaluate pre-funded common stock warrants and common stock warrants issued in connection direct financing to determine whether such warrants qualify for equity classification, or meet the definition of a derivative instrument, classified as a liability on the Balance Sheets and measured at fair value at inception and at each reporting date with changes in fair value recognized in the Statements of Operations and Comprehensive Loss in the period of change.
Direct Offering Costs
Direct offering costs consist principally of commissions, placement fees and other expenses, including other professional expenses incurred. We evaluate the terms under the financing agreement to determine the classification of direct costs in the accompanying Balance Sheets or accompanying Statements of Operations and Comprehensive Loss or some combinations of both.
Emerging Growth Company and Smaller Reporting Company Status
We are currently an “emerging growth company” as defined in the JOBS Act. Under the JOBS Act, companies have extended transition periods available for complying with new or revised accounting standards. We have elected this exemption to delay adopting new or revised accounting standards. We will remain an emerging growth company until the earlier of (1) December 31, 2026, (2) the last day of the fiscal year in which we have total annual gross revenues of at least $1.235 billion, (3) the date on which we are deemed to be a “large accelerated filer” as defined in Rule 12b-2 under the Exchange Act, or (4) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period. Based on these variables, we will cease being an emerging growth company as of December 31, 2026.
An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company:
30
We have elected to take advantage of certain of the reduced disclosure obligations in this Report on Form 10-Q and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may differ from the information provided by other public reporting companies in which they hold equity interests.
We are also a “smaller reporting company,” meaning that the market value of our stock held by non-affiliates plus the proposed aggregate amount of gross proceeds to us is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (1) the market value of our stock held by nonaffiliates is less than $250.0 million or (2) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, like emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Recently Issued and Adopted Accounting Pronouncements
There were no new accounting pronouncements that were issued or became effective since the issuance of our 2025 Annual Report that had, or are expected to have, a material impact on our unaudited condensed balance sheets, unaudited condensed statement of operations or unaudited condensed statement of cash flows.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
The disclosures in this Item are not required because we qualify as a smaller reporting company under federal securities laws.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of September 30, 2026. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of September 30, 2026.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the three months ended September 30, 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
31
Part II – OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be involved in various legal actions, including claims and proceedings arising in the ordinary course of business. We are currently not a party to any legal proceedings, the adverse outcome of which, in management’s opinion, individually or in the aggregate, would have a material adverse effect on our results of operations or financial position, and, to the best of management’s knowledge, no such litigation is currently pending or threatened.
Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors.
Item 1A. Risk Factors
An investment in our securities is speculative and involves a high degree of risk. You should carefully consider the risk factors below, as well as the other information in this Report, including our unaudited interim condensed financial statements and the related notes and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and in our other public filings in evaluating our business, including those risk factors included in our 2025 Annual Report and our other filings with the SEC. The occurrence of any of the events or developments described in our 2025 Annual Report, or summarized below or described elsewhere in this Report or otherwise in our SEC filings could harm our business, financial condition, results of operations, growth prospects or stock price. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and the market price of our common stock.
Risk Factors Summary
The following is a summary of principal factors and uncertainties that make investing in shares of our common stock risky and impact our ability to execute on our business strategy include risks regarding the following. This summary is not exhaustive, and readers are therefore encouraged to review the “Risk Factors” section herein and the “Risk Factors” section in our 2025 Annual Report in their entirety:
32
33
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
34
Item 6. Exhibits
|
|
|
|
Incorporated by Reference |
||||||
Exhibit Number |
|
Exhibit Description |
|
Form |
|
File No. |
|
Exhibit |
|
Filing Date |
3.1 |
|
Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc. |
|
8-K |
|
001-40738 |
|
3.1 |
|
August 31, 2021 |
3.2 |
|
Amended and Restated Bylaws of RenovoRx, Inc. |
|
8-K |
|
001-40738 |
|
3.1 |
|
September 11, 2023 |
4.1 |
|
Specimen Stock Certificate evidencing the Shares of Common Stock |
|
S-1 |
|
333-258071 |
|
4.4 |
|
August 5, 2021 |
4.2 |
|
Form of Pre-Funded Common Stock Purchase Warrant |
|
8-K |
|
001-40738 |
|
4.1 |
|
April 3, 2023 |
4.3 |
|
Form of Common Stock Purchase Warrant |
|
8-K |
|
001-40738 |
|
4.2 |
|
April 3, 2023 |
4.4 |
|
Warrant to Purchase Common Stock of RenovoRx, Inc. |
|
8-K |
|
001-40738 |
|
10.3 |
|
January 29, 2024 |
4.5 |
|
RenovoRx Placement Agent Warrant |
|
8-K |
|
001-40738 |
|
10.5 |
|
January 29, 2024 |
4.6 |
|
Form of Pre-Funded Common Stock Purchase Warrant of RenovoRx, Inc. |
|
8-K |
|
001-40738 |
|
10.2 |
|
April 15, 2024 |
4.7 |
|
Form of Series A Warrant to Purchase Common Stock of RenovoRx, Inc. |
|
8-K |
|
001-40738 |
|
10.3 |
|
April 15, 2024 |
4.8 |
|
Form of Placement Agent Warrant to Purchase Common Stock of RenovoRx, Inc. |
|
8-K |
|
001-40738 |
|
10.5 |
|
April 15, 2024 |
4.9 |
|
Form of Underwriter Warrant issued in February 2025 Public Offering |
|
8-K |
|
001-40738 |
|
4.1 |
|
February 10, 2025 |
4.10 |
|
Form of Pre-Funded Warrant Issued to Investors in the March 2026 Private Placement |
|
8-K |
|
001-40738 |
|
4.1 |
|
March 23, 2026 |
4.11 |
|
Form of Milestone Warrant Issued to Investors in the March 2026 Private Placement |
|
8-K |
|
001-40738 |
|
4.2 |
|
March 23, 2026 |
10.1+ |
|
Amended and Restated 2021 Omnibus Equity Incentive Plan |
|
8-K |
|
001-40738 |
|
10.1 |
|
June 30, 2026 |
10.2+ |
|
Amended and Restated Outside Director Compensation Policy |
|
Filed herewith |
|
|
|
|
|
|
31.1 |
|
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
Filed herewith |
|
|
|
|
|
|
31.2 |
|
Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
|
Filed herewith |
|
|
|
|
|
|
32.1† |
|
Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
Furnished herewith |
|
|
|
|
|
|
32.2† |
|
Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
Furnished herewith |
|
|
|
|
|
|
101.INS |
|
Inline XBRL Instance Document-the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document |
|
Filed herewith |
|
|
|
|
|
|
35
101.SCH |
|
Inline XBRL Taxonomy Extension Schema with Embedded Linkbase Documents |
|
Filed herewith |
|
|
|
|
|
|
104 |
|
Cover Page formatted as Inline XBRL and contained in Exhibit 101 |
|
Filed herewith |
|
|
|
|
|
|
+ Indicates management contract or compensatory plan or arrangement.
† The certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
RenovoRx, Inc. |
|
|
|
|
Date: November 5, 2026 |
By: |
/s/ Shaun R. Bagai |
|
|
Shaun R. Bagai |
|
|
Chief Executive Officer |
|
|
(Principal Executive Officer) |
|
|
|
Date: November 5, 2026 |
By: |
/s/ Mark Voll |
|
|
Mark Voll |
|
|
Chief Financial Officer |
|
|
(Principal Financial Officer) |
37